Ground Swell Capital’s NeuroSense Therapeutics NRSN Stock Holding History

Ground Swell Capital’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,858	Closed	-$20.6K	–	80
2023 Q1	$20.6K	Buy	+11,858	New	+$19.7K	0.03%	41

Other funds holding NRSN

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

VPIM

Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Ground Swell Capital's NRSN Position: Q2 2023 in Review

Ground Swell Capital sold out of NeuroSense Therapeutics (NRSN) in Q2 2023, closing a stake of 11,858 shares — an estimated $20.6K sold.

Ground Swell Capital first reported a position in NRSN in Q1 2023 and held it in 1 quarter. The position peaked at $20.6K in Q1 2023. 6 funds tracked by Wall St. Rank hold NRSN as of Q2 2023.

Ground Swell Capital reported no remaining NeuroSense Therapeutics position as of Q2 2023 after selling out during the quarter.
Ground Swell Capital sold 11,858 NeuroSense Therapeutics shares in Q2 2023, an estimated $20.6K.
Ground Swell Capital first reported a position in NeuroSense Therapeutics in Q1 2023 and held it in 1 quarter.
Ground Swell Capital's NeuroSense Therapeutics position peaked at $20.6K in Q1 2023.
6 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2023.

Based on Ground Swell Capital's 13F filing for Q2 2023, filed 10 Aug 2023.